This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.
Pharmaceutical Companies Pharmaceuticals Treatment 
DrugBank
AUGUST 9, 2024
Investment Trends in Pharmaceutical Research and Development Investing in the pharmaceutical sector presents a unique set of challenges and opportunities; let’s examine them in more detail. This can significantly impact a company's ability to recoup its R&D investment. reported in 2021. trillion by 2028.
Drug Discovery Today
JANUARY 22, 2021
A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.
113 
Drug Target Review
SEPTEMBER 7, 2023
The first clinical candidate, BSB-1001, aims to transform leukemia treatment by targeting minor histocompatibility antigen-1. Together, TCX-101 and TCX-102 allow BlueSphere to have a broader reach in the high-risk leukaemia treatment space where a high unmet medical need exists. The company is on track to file an IND in Q4 of 2023.
98 
DrugBank
NOVEMBER 4, 2024
The pharmaceutical industry is the primary source of antibiotic innovation; therefore, it must lead the way in combating resistance. Pharmaceutical companies are, therefore, exploring innovative approaches.
DrugBank
MARCH 7, 2024
Pharmaceutical researchers, in particular, have a keen interest in understanding the unfolding dynamics of this market. Inspired by its success, pharmaceutical companies are pursuing the development of drugs with similar therapeutic profiles, aiming to expand treatment options.
Fierce BioTech
OCTOBER 17, 2024
They’ll explore the benefits of a holistic, patient-centered strategy that embraces diverse patient needs, driving more timely treatments and maximizing the impact of marketing efforts. How a comprehensive, patient-focused strategy can not only improve treatment outcomes but also optimize the financial return on marketing investments.
Pharmaceutical Development Group
AUGUST 9, 2021
Formulation chemistry is the systematic and step-by-step approach to pharmaceutical development. Nowadays, as the usage of medicines is increasing, pharmaceutical companies are more eager to bring manufacturing a new look in quality and performance. There are different tests to assess the quality of a pharmaceutical product.
BioPharma Drive: Drug Pricing
OCTOBER 23, 2023
The Swiss pharmaceutical company has agreed to buy Televant, a company set up by Roivant and Pfizer to develop a promising inflammatory bowel disease treatment.
65 
Drug Target Review
AUGUST 6, 2024
Autoimmune diseases : Rheumatoid Arthritis : ADCs targeting specific immune cells or inflammatory mediators can provide more precise treatment options with potentially fewer side effects. Obesity : By targeting adipose tissue or specific metabolic pathways, ADCs could offer new treatments for obesity and related metabolic disorders.
117 
Antidote
JANUARY 3, 2024
While the primary goal of clinical trials is to help identify potential new treatments that improve people's health and save lives, it's the unfortunate truth that the patient experience is often not prioritized.
The Pharma Data
OCTOBER 9, 2021
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. 2 PsA can be a challenging disease to treat especially in younger populations, reinforcing the need for additional treatment options. A decision from the U.S.
52 
DrugBank
OCTOBER 17, 2024
By harnessing the vast amounts of data generated throughout the development pipeline, pharmaceutical companies can accelerate the discovery of novel therapies, optimize clinical trial design, enhance drug safety monitoring, and deliver personalized medicine, ultimately improving patient outcomes and transforming the future of healthcare.
The Pharma Data
FEBRUARY 8, 2021
Janssen Announces Treatment with ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer. ERLEADA ® is an androgen receptor (AR) inhibitor indicated for the treatment of patients with nmCRPC and for the treatment of patients with mCSPC. 10 months. [5]
52 
H1 Blog
JULY 24, 2023
How do pharmaceutical companies work with payers? In this blog post, we’ll take a closer look at how payer trends can reveal insights into the way patients use their medications – and how pharmaceutical companies can use this data to help improve patient outcomes.
DrugBank
MARCH 15, 2024
The weight loss industry has emerged as a major hub for innovative research, groundbreaking treatments, and economic opportunity. Mounjaro received approval as a treatment for diabetes in 2022, then in late 2023, under the brand name Zepbound (tirzepatide), it was approved for weight loss. With sales soaring to $2.2
The Pharma Data
MAY 27, 2022
In the pivotal clinical study CARTITUDE-1, 98 percent of patients with relapsed or refractory multiple myeloma responded to a one-time treatment with ciltacabtagene autoleucel and 80 percent of patients who responded experienced a stringent complete response . to develop and commercialise cilta-cel.[1].
52 
The Pharma Data
JANUARY 17, 2021
18 , 2021 /PRNewswire/ — Hanmi Pharmaceutical Co., plans to create a global R&D achievement based on innovations of inflammation–fibrosis treatment, Triple-acting new drug for NASH (non-alcoholic steatohepatitis) treatment as well as various other innovations in metabolic disease, oncology and rare disease fields.
52 
The Pharma Data
AUGUST 19, 2020
August 19, 2020 – Johnson & Johnson (NYSE:JNJ) today announced it has entered into a definitive agreement to acquire Momenta Pharmaceuticals, Inc. Momenta), a company that discovers and develops novel therapies for immune-mediated diseases, in an all cash transaction for approximately $6.5 NEW BRUNSWICK, N.J.,
52 
H1 Blog
DECEMBER 4, 2023
As the pharmaceutical and biotech industries continue to push for faster drug development, the importance of equity and diversity in clinical trial recruitment cannot be overlooked. With the rise of digital health and data, there are endless possibilities for reaching vulnerable populations and improving access to treatment.
The Pharma Data
NOVEMBER 8, 2020
FDA Approves Sesquient (fosphenytoin sodium) for the Treatment of Status Epilepticus in Adult and Pediatric Patients. PAOLI, Pa., — (BUSINESS WIRE) — November 9, 2020 – Sedor Pharmaceuticals, LLC (Sedor) today announced that the U.S. About Sedor Pharmaceuticals, LLC.
52 
The Pharma Data
JANUARY 3, 2021
03, 2021 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Ocumension Therapeutics, a China-based ophthalmic pharmaceutical company traded on the Stock Exchange of Hong Kong (1477.HK),
H1 Blog
MAY 4, 2023
Insights for Thought Leading Stakeholder Engagement to Decrease Medication Non-Adherence Pharmaceutical companies have long recognized the importance of engaging key opinion leaders (KOLs) to gain insight and support for clinical research, drug development, and medical education.
The Pharma Data
OCTOBER 9, 2021
Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced the U.S. The committee also voted unanimously to recommend use of maribavir for the treatment of refractory CMV infection and disease without genotypic resistance to ganciclovir, valganciclovir, foscarnet or cidofovir in transplant recipients.
52 
Altus Drug Development
JUNE 30, 2022
A focus on customers has always been one of the main pillars of the pharmaceutical industry. While this strategy is widely adopted by modern pharmaceutical companies, in recent years, its effectiveness has begun to wane. The onset of the covid-19 pandemic has caused considerable strain on the pharmaceutical industry as a whole.
The Pharma Data
DECEMBER 17, 2020
18, 2020 /PRNewswire/ — Camurus AB (NASDAQ STO: CAMX) announced today that the Swiss agency for therapeutic products, Swissmedic, has approved weekly and monthly Buvidal ® prolonged release buprenorphine for the treatment of opioid dependence in adults and adolescents from 16 years of age. LUND, Sweden , Dec. About Buvidal.
52 
The Pharma Data
MARCH 26, 2021
Despite continuous innovations in the treatment landscape, unmet needs remain. Overall, the number of treatment-emergent adverse events reported was similar between the ponesimod and teriflunomide treated groups, and the majority were mild/moderate and did not warrant treatment discontinuation. vs. 9.4%), nasopharyngitis (19.3%
52 
Advarra
APRIL 4, 2024
In the realm of pharmaceutical development, ensuring the safety and efficacy of new treatments is paramount. Traditionally, pharmaceutical sponsors have formed a new DSMB for each individual trial.
The Pharma Data
JANUARY 15, 2021
January 15, 2021 (HORSHAM, Pa.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. The study evaluated Darzalex Faspro® in combination with VCd, compared with VCd alone, a common treatment regimen used in adult patients with newly diagnosed AL amyloidosis.[5] Comenzo, M.D., Director, John C.
52 
Drug Target Review
OCTOBER 14, 2024
who shared his thoughts on the challenges faced by biotech companies in drug discovery, highlighting the critical role of data and technology in overcoming inefficiencies in the pharmaceutical industry. We interviewed Dr Neil Wilkie, CEO of Mironid Ltd.,
52 
The Pharma Data
MARCH 27, 2023
Entyvio ® should be used only in patients with inadequate response to conventional treatment. Injection 108mg Generic name vedolizumab(Genetical Recombination) Indications or effects Maintenance therapy for moderate to severe ulcerative colitis (The drug should be used only in patients with inadequate response to conventional treatment.)
40 
DrugBank
AUGUST 15, 2024
To effectively navigate this ecosystem and expedite the development of new therapies, collaboration between the pharmaceutical industry and academia is proving increasingly vital. This includes funding large-scale clinical trials and establishing robust manufacturing/distribution networks.
The Pharma Data
APRIL 19, 2022
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. Food and Drug Administration (“FDA”) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) for the treatment of schizophrenia.
The Pharma Data
AUGUST 19, 2020
19, 2020 /PRNewswire/ — Johnson & Johnson (NYSE:JNJ) today announced it has entered into a definitive agreement to acquire Momenta Pharmaceuticals, Inc. Momenta), a company that discovers and develops novel therapies for immune-mediated diseases, in an all cash transaction for approximately $6.5 NEW BRUNSWICK, N.J. ,
40 
The Pharma Data
NOVEMBER 23, 2021
Today’s approval helps meet a significant unmet medical need by providing a treatment option for this patient population.”. In the study, 352 transplant recipients with CMV infections who did not respond (with or without resistance) to treatment randomly received Livtencity or treatment assigned by a researcher for up to eight weeks.
52 
The Pharma Data
FEBRUARY 1, 2021
Medical professionals are desperately seeking effective treatments as hospitals are continuously overwhelmed with COVID-19 patients. One recently introduced, promising COVID-19 treatment is produced from the antibodies in the plasma of recently recovered virus patients.
52 
The Pharma Data
APRIL 4, 2023
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the availability of an additional tablet strength of ERLEADA ® (apalutamide) in the United States. Each person and their cancer are unique and, as such, there is no one-size-fits-all approach to treatment,” said Luca Dezzani, M.D.,
The Pharma Data
AUGUST 18, 2020
Johnson & Johnson statement on the launch of new CARE (Corona Accelerated R&D in Europe) consortium, Europe’s largest, multi-partner scientific research initiative dedicated to discovering and developing urgently needed treatment options for COVID-19. The reader is cautioned not to rely on these forward-looking statements.
52 
The Pharma Data
MARCH 2, 2021
Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. iii Current treatment options have limited efficacy in terms of weight loss or are often associated with adverse events. “We
52 
The Pharma Data
MARCH 15, 2022
For the Sarclisa ® subcutaneous formulation delivery, Sanofi has partnered with drug delivery technology innovator company Enable Injections , Inc. to advance the development of a subcutaneous delivery for Sarclisa ® with the goal of offering a unique patient-centric treatment experience. John Reed , MD , Ph.
52 
PPD
NOVEMBER 11, 2024
However, getting essential treatments to patients quickly and safely requires more than just technological innovation. A global network with local expertise To ensure the delivery of treatments to patients worldwide, biotech and biopharma companies also need partners that can provide comprehensive solutions from a geographic perspective.
PPD
JUNE 20, 2024
Acceleration in every step of clinical research is critical to pharmaceutical developers. Despite advances in technology and innovation, pharmaceutical leaders say that trials are increasingly complex, particularly when it comes to patient recruitment and site engagement.
The Pharma Data
APRIL 27, 2021
Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that that the U.S. FDA granted mobocertinib Orphan Drug Designation for the treatment of lung cancer with HER2 mutations or EGFR mutations including Exon20 insertion mutations. About Takeda Pharmaceutical Company Limited.
52 
The Pharma Data
DECEMBER 3, 2020
The TAK-620-303 (SOLSTICE) trial (NCT02931539) is a multicenter, randomized, open-label, active-controlled trial comparing eight weeks of treatment with either maribavir or investigator assigned treatment (IAT) in transplant recipients with CMV infection refractory or resistant to existing antiviral treatments (i.e.,
52 
The Pharma Data
APRIL 16, 2021
Opdivo in combination with Cabometyx was generally well tolerated, with a low rate of treatment-related discontinuations. The combination of Opdivo and Cabometyx was well tolerated, with safety reflective of the known profiles of both medicines and a low rate of treatment-related adverse events (TRAEs) leading to discontinuation.
52
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content